DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wv359t/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Alchemia Limited
- Alvogen, Inc.
- Aphios Corporation
- Cellceutix Corporation
- Enanta Pharmaceuticals, Inc.
- Helix BioMedix, Inc.
- LegoChem Biosciences, Inc
- Lytix Biopharma AS
- MGB Biopharma Limited
- Microbiotix, Inc.
- MicuRx Pharmaceuticals, Inc.
- Nabriva Therapeutics AG
- NovaBay Pharmaceuticals, Inc.
- NovoBiotic Pharmaceuticals, LLC
- Oragenics, Inc.
- Sealife PHARMA GMBH
- Sentinella Pharmaceuticals, Inc.
- TAXIS Pharmaceuticals, Inc.
- Wockhardt Limited
Drug Profiles
- auriclosene
- brilacidin tetrahydrochloride
- chrysophaentin
- closthioamide
- EDP-788
- Epimerox
- HB-1345
- HT-01
- HT-02
- IBN-1
- LCB-010371
- LCB-010699
- lefamulin
- LTX-109
- Marinus
- MBX-1162
- MGBBP-3
- MRX-I
- MU-1140
- NAI-107
- NAI-603
- SLP-0904
- SLP-0905
- Small Molecule for Bacterial Infections
- Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections
- Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections
- Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections
- SP-2078
- Teixobactin
- TXA-709
- WCK-4086
For more information visit http://www.researchandmarkets.com/research/wv359t/vancomycinresista
